Piper Sandler Companies Stock Earnings Reports

Piper Sandler reported a strong start to 2026 with adjusted net revenues of $470 million, marking the tenth consecutive quarter of year-over-year revenue growth. Corporate Investment Banking led performance (revenues up 30% y/y to $324M), driven by robust corporate financings and record Healthcare franchise results (medtech, biopharma, Healthcare IT & Services). Advisory fees set a first-quarter record ($251M, +16% y/y) with top rankings in U.S. bank and medtech M&A for the quarter. Corporate Financing and equity underwriting were also strong (36 financings raising $14B), though management expects corporate financing and overall capital markets revenue to moderate in Q2 from a high Q1. Public Finance and Fixed Income faced headwinds (Municipal financing down 9%; fixed income pressured by volatility), while Equity Brokerage posted record Q1 revenues ($60M). Non-M&A advisory (Debt Capital Markets Advisory, Private Capital Advisory, restructuring) contributed meaningfully, with Debt Capital Markets especially strong. Operating income was $94M (20% margin), net income $72M, adjusted EPS $1; operating income grew 37% y/y. Compensation ratio improved to 61.6% (90 bps better y/y). Non-compensation expenses rose in part due to an $8.5M litigation charge related to a California municipal finance lawsuit. Capital returns were substantial: $171M returned (including $101M dividends and $70M buybacks), and the Board approved a $0.20 quarterly dividend (14% increase). Headcount and talent investments continued (192 investment banking MDs, promotions and hires). Management remains cautiously optimistic: pipelines are healthy but timing of transactions is sensitive to market volatility and macro/geopolitical uncertainty; they expect Q2 advisory to be similar to Q1 and foresee some sequential decline in corporate financing revenues.